Avastin News and Research

RSS
Avastin is a biologic antibody designed to specifically bind to a protein called vascular endothelial growth factor (VEGF) that plays an important role throughout the lifecycle of the tumor to develop and maintain blood vessels, a process known as angiogenesis. Avastin is designed to interfere with the blood supply to a tumor by directly binding to the VEGF protein to prevent interactions with receptors on blood vessel cells. Avastin does not bind to receptors on normal or cancer cells. The tumor blood supply is thought to be critical to a tumor’s ability to grow and spread in the body (metastasize).
VBL Therapeutics reports positive results from VB-111 Phase 1/2a study in recurrent platinum-resistant Müllerian cancer

VBL Therapeutics reports positive results from VB-111 Phase 1/2a study in recurrent platinum-resistant Müllerian cancer

Additional preclinical data on DelMar’s VAL-083 to treat temozolomide-resistant GBM presented at AACR

Additional preclinical data on DelMar’s VAL-083 to treat temozolomide-resistant GBM presented at AACR

DelMar to present new data on development of VAL-083 at 2015 ASCO Annual Meeting

DelMar to present new data on development of VAL-083 at 2015 ASCO Annual Meeting

First new treatment authorised in a decade for advanced cervical cancer patients in the UK

First new treatment authorised in a decade for advanced cervical cancer patients in the UK

Imperial scientists develop new test that uses human stem cells to predict side effects of drugs

Imperial scientists develop new test that uses human stem cells to predict side effects of drugs

Johns Hopkins researcher helps discover effectiveness of three drugs for treating patients with DME

Johns Hopkins researcher helps discover effectiveness of three drugs for treating patients with DME

UW ophthalmology researchers help show effectiveness of three drugs for treating DME

UW ophthalmology researchers help show effectiveness of three drugs for treating DME

Clinical study comparing effectiveness of three standard treatments for DME published in NEJM

Clinical study comparing effectiveness of three standard treatments for DME published in NEJM

Actavis provides overview of standalone global pharmaceutical development pipeline

Actavis provides overview of standalone global pharmaceutical development pipeline

Mathematical models of cancer behavior offer new insights on tumor growth

Mathematical models of cancer behavior offer new insights on tumor growth

CytRx reports positive interim results from aldoxorubicin Phase 2 trial for treatment of GBM

CytRx reports positive interim results from aldoxorubicin Phase 2 trial for treatment of GBM

CTRC researcher receives special $1.62 million orphan disease grant from FDA

CTRC researcher receives special $1.62 million orphan disease grant from FDA

Open payments database debuts, detailing financial connections between physicians and drug makers

Open payments database debuts, detailing financial connections between physicians and drug makers

Cochrane Review rejects safety concerns regarding cheap alternative drug for treating eye disease

Cochrane Review rejects safety concerns regarding cheap alternative drug for treating eye disease

AstraZeneca is developing new PARP inhibitor for treatment of ovarian cancer

AstraZeneca is developing new PARP inhibitor for treatment of ovarian cancer

Bypassing politics, insurers pay for end of life talks

Bypassing politics, insurers pay for end of life talks

Colorectal cancer therapies market to remain constant at $7.7 billion by 2023

Colorectal cancer therapies market to remain constant at $7.7 billion by 2023

New treatment for ovarian cancer can improve response rates

New treatment for ovarian cancer can improve response rates

Medicare to pay for hep C screenings for baby boomers

Medicare to pay for hep C screenings for baby boomers

First Edition: June 3, 2014

First Edition: June 3, 2014